Illumina (ILMN) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $29.20B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Jacob Thaysen |
| IPO Date | 2000-07-28 | CAGR | 42.03% |
| Employees | 8,600 | Website | www.illumina.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.01% | Total Yield | 0.01% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $27.21B | P/E | 38.37 | Forward P/E | 31.94 | PEG | 5.66 |
| P/S | 2477.52 | P/B | 4112.02 | P/CF | 9751.84 | P/FCF | 10991.92 |
| Sales | $4.39B | Sales 1Y | 1.25% | Sales 3Y | -1.26% | Sales 5Y | 26.43% |
| EPS | $5.03 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | 28.79% |
| Sales QoQ | -5.95% | EPS QoQ | -59.91% | Sales QoQ Avg | 1.29% | EPS QoQ Avg | 27.85% |
| Gross Margin | 67.66% | Operating Margin | 21.45% | Profit Margin | 19.43% | ROCE | 18.87% |
| ROA | 13% | ROE | 34% | Altman Z Score | 5.81 | Piotroski Score | 7 |
| Current Ratio | 1.75 | Quick Ratio | 1.36 | Cash Ratio | 0.7 | Op. CF Ratio | 0.18 |
| Debt/Equity | 0.92 | Debt/Assets | 0.38 | Lt Debt/Equity | 0.73 | Lt Debt/Cap. | 0.36 |
| Intrst Cov. | 12.39 | Inventory Turnover | 2.32 | Asset Turnover | 0.67 | Receivables Turnover | 5.95 |
| Enterprise Value | $27.21B | P/E Ratio | 38.37 |
| Forward P/E | 31.94 | PEG Ratio | 5.66 |
| P/S Ratio | 2477.52 | P/B Ratio | 4112.02 |
| P/CF Ratio | 9751.84 | P/FCF Ratio | 10991.92 |
| EPS | $5.03 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | 28.79% |
| Revenue Growth 1Y | 1.25% | Gross Margin | 0.68% |
| Operating Margin | 0.21% | Profit Margin | 0.19% |
| ROE | 0.34% | ROA | 0.13% |
| ROCE | 0.19% | Current Ratio | 1.75 |
| Quick Ratio | 1.36 | Cash Ratio | 0.7 |
| Debt/Equity | 0.92 | Interest Coverage | 12.39 |
| Altman Z Score | 5.81 | Piotroski Score | 7 |
Illumina (ILMN) valuation & financials
Illumina (ILMN) has a market capitalization of $29.20B and trades at a price-to-earnings ratio of 38.4. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Illumina's revenue grew +1.2% over the last year.
Illumina's next earnings report is scheduled for July 30, 2026 after market close; analysts estimate EPS of $1.24.
Illumina (ILMN) — frequently asked questions
When does Illumina (ILMN) report earnings next?
Illumina is expected to report earnings on July 30, 2026 after market close. Analysts estimate EPS of $1.24.
What is Illumina's market cap?
Illumina (ILMN) has a market capitalization of $29.20B.
What is ILMN's P/E ratio?
Illumina trades at a price-to-earnings ratio of 38.4, with trailing twelve-month EPS of $5.03.
How fast is Illumina growing?
Illumina's revenue grew +1.2% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)